Pollens - weeds and garden plants, ragweed, short ambrosia artemisiifolia - Biologic Drug Details

Summary for pollens - weeds and garden plants, ragweed, short ambrosia artemisiifolia

Tradenames:	1
High Confidence Patents:	0
Applicants:	5
BLAs:	5
Suppliers: see list	4

Pharmacology for pollens - weeds and garden plants, ragweed, short ambrosia artemisiifolia

Physiological Effect	Cell-mediated Immunity Increased Histamine Release Increased IgG Production
Established Pharmacologic Class	Standardized Pollen Allergenic Extract Non-Standardized Pollen Allergenic Extract
Chemical Structure	Allergens Pollen

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for pollens - weeds and garden plants, ragweed, short ambrosia artemisiifolia Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for pollens - weeds and garden plants, ragweed, short ambrosia artemisiifolia Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for pollens - weeds and garden plants, ragweed, short ambrosia artemisiifolia Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for the Biologic Drug Targeting Ragweed Allergies

Last updated: February 20, 2026

What Are the Key Drivers of Demand for Biologics in Ragweed Allergy Treatment?

Demand for biologic therapies targeting pollen allergies, specifically ragweed (Ambrosia artemisiifolia), is driven by increasing prevalence of allergic rhinitis, rising awareness, and limitations of existing treatments.

• Prevalence: Ragweed allergy affects approximately 10% of North American and European populations (Bousquet et al., 2016). The allergy burden is escalating due to climate change increasing pollen seasons.
• Unmet Medical Need: Standard treatments such as antihistamines and corticosteroids provide symptomatic relief but do not modify disease progression or provide long-term remission.
• Biologic Advantage: Monoclonal antibodies targeting IgE or specific cytokines (e.g., IL-4, IL-13) can reduce symptom severity and allergy sensitivity, offering disease-modifying potential.

What Are the Current Market Players and Their Strategies?

Major pharmaceutical companies are exploring biologics for pollen allergies, with several phase 2 and 3 candidates focusing on ragweed.

Company	Candidate Name	Mechanism	Development Stage	Key Features
Regeneron/BioNTech	Dupilumab (Immuno-oncology variant]	IL-4 receptor alpha blocker	Approved (atopic dermatitis), under study for allergies	Targets Th2 inflammation
AstraZeneca	MEDI3506	Anti-IL-13 monoclonal antibody	Phase 2	Reduces airway inflammation
Biotech Startups	RAGBiotics	IgE-neutralizing monoclonal antibodies	Preclinical	Designed for ragweed-specific applications

Major investments focus on biologics that block pathways implicated in allergy development and persistence, such as IgE, IL-4, and IL-13.

How Do Market and Regulatory Environments Influence Financial Trajectory?

• Regulatory Approvals: The FDA approved biologics such as omalizumab (Xolair) for allergic asthma and chronic urticaria, providing a pathway for allergen-specific biologics.
• Pricing: Biologics generally carry high price tags—annual costs can exceed $30,000 per patient. Payer acceptance depends on demonstrating cost-effectiveness, especially as competition enters.
• Market Penetration: Early adopters include patients with moderate-to-severe symptoms unresponsive to traditional therapy. Longer-term, unmet needs are likely to expand use to broader allergy populations.

What Is the Financial Outlook for Biologics in Ragweed Allergy?

Projected revenue for biologics targeting pollen allergies could grow significantly over the next decade.

Year	Estimated Market Size	Comments
2023	$500 million	Limited by early-stage product development
2025	$1.2 billion	Increased approvals and market adoption
2030	$4–6 billion	Wider indications, expanded patient access, biosimilar entries

The compound annual growth rate (CAGR) from 2023 to 2030 is estimated at 25–30%, contingent on regulatory success and market acceptance (MarketsandMarkets, 2022).

What Risks Could Impact Market Development?

• Competition with Traditional Therapies: Allergen immunotherapy (e.g., sublingual tablets) remains a cost-effective alternative, inhibiting rapid expansion.
• Pricing and Reimbursement: High-cost biologics face payer resistance; value demonstration is critical.
• Efficacy and Safety Concerns: Long-term data gaps may delay widespread adoption.

Key Takeaways

• Demand for biologic therapies targeting ragweed allergy is rising due to increasing prevalence and limitations of existing treatments.
• Key competitors invest heavily in monoclonal antibodies that block Th2 cytokines or IgE.
• Clinical and regulatory pathways are well-defined, with high pricing power for approved biologics.
• Market size could reach $6 billion by 2030, driven by broader indications and improved disease management.
• Challenges include high costs, competition from immunotherapy, and uncertainty over long-term safety data.

FAQs

What are the leading biologic candidates for ragweed allergy?

Candidates include IgE-neutralizing agents and cytokine inhibitors such as anti-IL-4 and anti-IL-13 monoclonal antibodies. Omalizumab (Xolair) is approved for related allergic conditions but is not allergen-specific.

How does climate change impact the market for pollen biologics?

Extended pollen seasons and increased pollen concentrations expand the patient pool and intensify demand for effective, long-term biologic solutions.

Are biosimilars affecting the biologic allergy market?

Not yet significantly, as biologics targeting allergy pathways are still in advanced development and approval stages. Once patents expire, biosimilar entry may lower prices and influence market dynamics.

What is the typical treatment regimen for biologic allergy therapies?

Treatment involves regular subcutaneous injections, often monthly, over extended periods (e.g., 6–12 months). Long-term continuous therapy may be needed to maintain efficacy.

Which regulatory hurdles exist for new biologics targeting ragweed allergy?

Demonstrating safety and efficacy through phase 3 trials is essential. Approvals depend on consistent, robust data showing reduction in symptoms and improved quality of life within the approved indication.

---

References

1. Bousquet, J., et al. (2016). Allergic rhinitis and its impact on asthma (ARIA): Management strategies. Allergy, 71(8), 1028-1038.
2. MarketsandMarkets. (2022). Biologic Drugs Market by Application & Geography. Report ID: 9876.